Company intelligence / Profile preview

Aeremedea

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Aeremedea is a biotechnology company focused on developing novel therapies for rare diseases, with a primary emphasis on cystic fibrosis. The company's lead program, AER-001, is a small molecule designed to address the underlying cause of cystic fibrosis by modulating the CFTR protein. Aeremedea aims to provide transformative treatments for patients with high unmet medical needs through innovative drug discovery and development. The company is led by a team of experienced biopharmaceutical executives with a track record of success in the rare disease space.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Aeremedea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeremedea.

Explore the full profile